Epidemiology of Pneumococcal Disease Following PCV13 Recommendations
The CDC recommends the use of the 13-valent pneumococcal vaccine (PCV13) for adults aged 19 years or older with immunocompromising conditions (ICs) and adults aged 65 years and older with increased disease risks. A recent study evaluated the epidemiology of pneumococcal disease following PCV13 recommendations in older adults, those with ICs, and continued routine use of PCV13 in children. Read more.

RSV Testing in Older Adults With Respiratory Disease
The FDA recently approved the first vaccine to protect against lower respiratory tract disease caused by respiratory syncytial virus (RSV). According to a recent study, the burden of RSV in older adults has been greatly underestimated, partly due to low levels of RSV testing among adults hospitalized for lower respiratory tract infection in the United States. Read more.

Vaccination Against Mpox Effective; CDC Recommends Two Doses
As of the end of March, more than 30,000 monkeypox (mpox) cases had been reported in the United States in an outbreak that has disproportionately affected gay, bisexual, and other men who have sex with men, as well as those who are transgender. Learn more about the results of a recent study published in Morbidity & Mortality Weekly Report.